Get the Stockscreener App
83.12
0.25%
0.21
Pre-market:
82.62
-0.50
-0.60%
Corcept Therapeutics Inc stock is traded at $83.12, with a volume of 1.04M.
It is up +0.25% in the last 24 hours and up +47.45% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
See More
Previous Close:
$82.91
Open:
$82.91
24h Volume:
1.04M
Relative Volume:
0.75
Market Cap:
$8.92B
Revenue:
$769.10M
Net Income/Loss:
$46.67M
P/E Ratio:
237.49
EPS:
0.35
Net Cash Flow:
$119.79M
1W Performance:
+13.35%
1M Performance:
+47.45%
6M Performance:
-4.79%
1Y Performance:
+18.64%
1-Day Range:
$79.40
$83.68
1-Week Range:
$73.62
$84.79
52-Week Range:
$28.66
$91.00
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
83.12 | 8.92B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Dec-31-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-25 | Initiated | UBS | Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
CORT Stock Skyrockets 35% After Early FDA Nod For Ovarian Cancer Drug - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Korlym improves results for diabetes patients taking GLP-1 drugs - Cushing's Disease News
Catalyst and Momentum Trials Data Fuels Optimism for Corcept Therapeutics (CORT) - Yahoo Finance
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits
Norges Bank Purchases New Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Clearbridge Investments LLC Has $17.66 Million Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT to resubmit NDA for relacorilant in Cushing's syndrome, stock up - MSN
7 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
CORT Stock Rises 42% in a Month: Here's What You Should Know - The Globe and Mail
Corcept Therapeutics (CORT) Reveals Promising Trial Data on Diab - GuruFocus
Corcept Therapeutics (CORT) Reveals Promising Trial Data on Diabetes Treatment - GuruFocus
Geode Capital Management LLC Acquires 734,646 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym® - Lelezard
Legal & General Group Plc Decreases Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics Stock On Fire: Up 36% With 12-Day Winning Streak - Trefis
CORT Stock Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Corcept Therapeutics Stock 12-Day Winning Spree: Stock Climbs 36% - Trefis
Corcept Therapeutics chief development officer sells $1.41m stock By Investing.com - Investing.com Australia
Corcept Therapeutics chief development officer sells $1.41m stock - Investing.com UK
Adrenocortical Carcinoma Market Forecast Signals Robust - openPR.com
Adrenocortical Carcinoma Market Forecast Signals Robust Industry Growth Through 2036 – DelveInsight | Orphagen Pharma, Corcept Therapeutics, Cytovation, Merck, Enterome, Bristol-Myers Squibb, UNICANCE - Barchart
Corcept (NASDAQ: CORT) CDO sells 20K shares under 10b5-1 plan - Stock Titan
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio? - The Motley Fool
Corcept Faces Amended Qui Tam Complaint After DOJ Exit - The Globe and Mail
Corcept Therapeutics president Sean Maduck sells $1.76m in stock - Investing.com UK
11-Day Rally Sends Corcept Therapeutics Stock Up 32% - Trefis
Corcept Therapeutics Stock Surges 32%, With A 11-Day Winning Spree - Trefis
Corcept Therapeutics president Sean Maduck sells $1.76m in stock By Investing.com - Investing.com Australia
Corcept Therapeutics CFO sells $2.8m in company stock - Investing.com
Corcept Therapeutics CFO sells $2.8m in company stock By Investing.com - Investing.com Australia
Corcept (NASDAQ: CORT) officer reports stock grants and tax share withholding - Stock Titan
Corcept (NASDAQ: CORT) CDO acquires 1,754 shares via grant and purchase plan - Stock Titan
Corcept (CORT) officer sells 25K shares after option exercise under 10b5-1 plan - Stock Titan
Corcept Therapeutics (CORT) CFO executes 40,000-share option exercise-and-sale under 10b5-1 plan - Stock Titan
Corcept (NASDAQ: CORT) CBO reports equity awards and tax-share withholding - Stock Titan
[8-K] CORCEPT THERAPEUTICS INC Reports Material Event - Stock Titan
DOJ Declines Intervention in Qui Tam Suit Against Corcept; Relator Amends Complaint - TradingView
Corcept Therapeutics Stock 10-Day Winning Spree: Stock Climbs 29% - Trefis
Corcept Therapeutics Stock On Fire: Up 29% With 10-Day Winning Streak - Trefis
Corcept (NASDAQ: CORT) CEO trust sale and 600,000-share gifts disclosed - Stock Titan
Corcept (CORT) insider resale notice: 20,000 shares via option exercise (06/02/2026) - Stock Titan
Corcept Therapeutics Stock On Fire: Up 21% With 9-Day Winning Streak - Trefis
H.C. Wainwright Keeps Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail
H.C. Wainwright reiterates Corcept stock rating on ASCO data By Investing.com - Investing.com Canada
Corcept Therapeutics Stock Surges 28%, With A 9-Day Winning Spree - Trefis
CORT (NASDAQ: CORT) Rule 144 notice: 160,000 shares via Stifel - Stock Titan
Joseph Belanoff sells 66,198 CORT shares; Form 144 filed (CORT) - Stock Titan
Corcept Therapeutics Insider Sold Shares Worth $325,000, According to a Recent SEC Filing - Moomoo
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $88 - Moomoo
Corcept Therapeutics Insider Sold Shares Worth $4,918,944, According to a Recent SEC Filing - Moomoo
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):